July, 2024
July 2024
9 Posts You Should Not Miss From Day 3 of ESMOGI24!
Jun 30, 2024, 08:07

9 Posts You Should Not Miss From Day 3 of ESMOGI24!

ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024, as well as online, through a dedicated virtual platform. The congress will be the place to present impactful new data in GI oncology.

Our team at OncoDaily has compiled a list of posts from the 3rd day of this conference that you should not miss!

Lizzy Smyth

ESMOGI24 loves surgeons! Magnus Nilsson discusses when and why we should operate in esophageal cancer. Multidisciplinary research is critical to improve outcomes.


Megan Barnet

Biological rationale of EGFR-MET Bispec Ab Amivantamab with Josep Tabernero; averting met-amplification rel. resistance, inducing ADCC. We will test in 1L Phase 3 ORIGAMI-2 trial with platinum doublet vs CT/cetux in RAS/BRAFwt L-sided mCRC opening soon.


Angela Lamarca

Modulating microbiome in Gastrointestinal Cancers by Elena Elez at ESMOGI24. Evidence is supportive. Bringing this to trials and clinical practice is very challenging. We will need to work with other specialist to become this a reality.


Myriam Chalabi

Great discussion by Juan O’Connor in the mini-oral session at ESMOGI24. Putting NEST-1 and ECOG study into perspective. Also for highlighting our TARZAN trial with atezo/bev in rectal cancer for organ preservation (42% OP rate in 38 pMMR patients).


Cathy Eng

Excellent discussion from Shouki Bazarbashi on Regina Phase 2 LBA interim analysis of rego+nivo+5×5 XRT in rectal cancer from my friend. Dr. Francesco Sclafani with intriguing data as well!


Pashtoon Kasi

NEST Trial responses to date. What’s particularly of note is the deepening of the responses with longer time to brew. The pattern and lack of recurrence speaks to curative potential of immunotherapy for both MSS and MSI-High tumors.


Michel Ducreux 

Mitazalimab (anti-CD40) added to FOLFIRINOX: impressive results. The next step for the treatment of metastatic pancreatic cancer? Great talk given at ESMOGI24 by Teresa Macarulla.


Lorenza Rimassa

Zev Wainberg discussing the 3-year OS data from the TOPAZ-1 trial in biliary tract cancer and the OPTIMIZE-1 in pancreatic cancer. Which are the open questions and future perspectives?


Seyed Alireza Javadinia

Oesophago-gastric cancer was one of the main topics covered on the third day of ESMO – European Society for Medical Oncology GI2024.

In this session, Professors Magnus Nilsson, Florian Lordick, Muro Kei, and Elizabeth Smyth talked about various aspects of this very challenging subgroup of patients. This session was chaired by Professors Sylvie Lorenzen and Pr Adda Bounedjar.

Initially, Dr. Nilsson discussed about “Non-operative management for patients with oesophageal cancer with cCR after neoadjuvant CT/RT,” which seems to be a hard task for a GI surgeon.

Then, Professors Florian Lordick talked about current data on “Neoadjuvant and adjuvant treatment of oesophageal and gastric cancer,” which was a really evolving field with too many upcoming data.

Subsequently, Dr Mura and Dr Elizabeth Smyth discussed the treatment of advanced oesophageal cancer and gastric in 2024!